BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 24,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 24,000 shares of the company’s stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $95.86, for a total value of $2,300,640.00. Following the sale, the chief executive officer owned 63,209 shares of the company’s stock, valued at approximately $6,059,214.74. The trade was a 27.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total value of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total value of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total value of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total transaction of $3,227,730.00.

BioNTech Stock Down 0.5%

Shares of NASDAQ:BNTX traded down $0.48 during midday trading on Wednesday, hitting $95.25. 827,996 shares of the company’s stock traded hands, compared to its average volume of 1,087,206. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a market cap of $24.09 billion, a PE ratio of -12.16 and a beta of 1.25. The firm’s fifty day moving average price is $99.01 and its two-hundred day moving average price is $95.10. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period last year, the company posted ($1.60) earnings per share. The firm’s revenue for the quarter was down 59.5% on a year-over-year basis. On average, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently made changes to their positions in the business. AlphaCentric Advisors LLC increased its position in shares of BioNTech by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock worth $499,000 after purchasing an additional 305 shares during the last quarter. USS Investment Management Ltd grew its stake in BioNTech by 1.2% in the first quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock worth $2,854,000 after purchasing an additional 382 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in BioNTech in the second quarter worth about $39,000. Marks Group Wealth Management Inc increased its holdings in BioNTech by 16.0% in the first quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock valued at $307,000 after buying an additional 476 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in BioNTech by 1,012.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after buying an additional 506 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BNTX has been the subject of a number of recent research reports. Berenberg Bank set a $140.00 target price on BioNTech in a research note on Wednesday, September 16th. Citigroup decreased their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Morgan Stanley decreased their target price on shares of BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $125.69.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.